U.S. flag

An official website of the United States government

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 7 books (19 items)

1.
PDQ Cancer Information Summaries [Internet].

PDQ Cancer Information Summaries [Internet].

Bethesda (MD): National Cancer Institute (US); 2002-.

Table of Contents

2.
Selumetinib (Koselugo): CADTH Reimbursement Recommendation: Indication: For the treatment of pediatric patients aged 2 years and above, with neurofibromatosis type 1 who have symptomatic, inoperable plexiform neurofibromas [Internet].

Selumetinib (Koselugo): CADTH Reimbursement Recommendation: Indication: For the treatment of pediatric patients aged 2 years and above, with neurofibromatosis type 1 who have symptomatic, inoperable plexiform neurofibromas [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2023 May.

Table of Contents

3.
Amivantamab (Rybrevant): CADTH Reimbursement Recommendation: Indication: For the treatment of adult patients with locally advanced or metastatic non–small cell lung cancer with activating epidermal growth factor receptor exon 20 insertion mutations whose disease has progressed on, or after platinum-based chemotherapy [Internet].

Amivantamab (Rybrevant): CADTH Reimbursement Recommendation: Indication: For the treatment of adult patients with locally advanced or metastatic non–small cell lung cancer with activating epidermal growth factor receptor exon 20 insertion mutations whose disease has progressed on, or after platinum-based chemotherapy [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2023 Mar.

Table of Contents

4.
Antiretroviral Therapy for HIV Infection in Infants and Children: Towards Universal Access: Recommendations for a Public Health Approach: 2010 Revision.

Antiretroviral Therapy for HIV Infection in Infants and Children: Towards Universal Access: Recommendations for a Public Health Approach: 2010 Revision.

Geneva: World Health Organization; 2010.

Table of Contents

5.
Osimertinib (Tagrisso): CADTH Reimbursement Recommendation: Indication: As adjuvant therapy after tumour resection in patients with stage IB-IIIA non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations [Internet].

Osimertinib (Tagrisso): CADTH Reimbursement Recommendation: Indication: As adjuvant therapy after tumour resection in patients with stage IB-IIIA non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Jan.

Table of Contents

6.
Antiretroviral Therapy for HIV Infection in Adults and Adolescents: Recommendations for a Public Health Approach: 2010 Revision.

Antiretroviral Therapy for HIV Infection in Adults and Adolescents: Recommendations for a Public Health Approach: 2010 Revision.

Geneva: World Health Organization; 2010.

Table of Contents

7.
Pemigatinib (Pemazyre): CADTH Reimbursement Recommendation: Indication: For the treatment of adults with previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma with a FGFR2 fusion or other rearrangement [Internet].

Pemigatinib (Pemazyre): CADTH Reimbursement Recommendation: Indication: For the treatment of adults with previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma with a FGFR2 fusion or other rearrangement [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Apr.

Table of Contents

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Search details

See more...

Recent activity